Roche received approval from the European Commission for RoActemra (tocilizumab, known as Actemra outside of the EU), to treat patients with rheumatoid arthritis (RA). RoActemra, in combination with methotrexate (MTX), is indicated for the treatment of adult patients with moderate to severe RA who have not responded to, or were intolerant of previous therapy with one or more disease modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists. RoActemra is the first interl...